The Immune Atlas identifies immune signatures in MM, enhancing outcome prediction and guiding personalized therapies by ...
In this secondary analysis of the ECOG-ACRIN E2906 study, researchers assessed vulnerabilities of AML patients aged 60 years or older and their affect on survival outcomes.
Researchers evaluated sex differences in clinical features and chromosomal abnormalities in 850 patients with newly diagnosed multiple myeloma.
According to the IAEA’s latest bulletin, the work focused on clinical applications of biodosimetry — the use of biological ...
RYTELO® (imetelstat) net product revenue expected in the range of $220 to $240 million2026 total operating expenses expected in the range of ...
Daratumumab-lenalidomide maintenance significantly increases MRD-negative conversion and reduces progression risk in multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback